RITUXIMAB, TACROLIMUS , PREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion. clinical trials

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

This study is testing a new medicine called obinutuzumab for a kidney condition called minimal change disease. We want to see if it works as well as, or better than, current treatments, and if it's safe for adults.